The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia

Leukemia Research

Volumn 37, Issue 10, 2013, Pages 1200-1207

  Gruhn, Bernd ^a   Naumann, Thomas ^a   Gruner, Dorothee ^a   Walther, Mario ^a   Wittig, Susan ^a   Becker, Sabine ^a   Beck, James F ^a   Sonnemann, Jürgen ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Childhood ALL; Gene expression; HDAC; Prednisone response; Vorinostat

Indexed keywords

ETOPOSIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; ISOPROTEIN; METHOTREXATE; PREDNISONE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CELL DEATH; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; DRUG TARGETING; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HDAC GENE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; SINGLE DRUG DOSE; T CELL LEUKEMIA;

CHILDHOOD ALL; GENE EXPRESSION; HDAC; PREDNISONE RESPONSE; VORINOSTAT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASES; HUMANS; INFANT; ISOENZYMES; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; REPRESSOR PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883559178     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.016     Document Type: Article

References (43)

1. Gatta G., Zigon G., Capocaccia R., Coebergh J.W., Desandes E., Kaatsch P., et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009, 45:992-1005.
2. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
3. Masetti R., Serravalle S., Biagi C., Pession A. The role of HDACs inhibitors in childhood and adolescence acute leukemias. J Biomed Biotechnol 2011, 2011:148046.
4. Stimson L., Wood V., Khan O., Fotheringham S., La Thangue N.B. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009, 20:1293-1302.
5. Mercurio C., Minucci S., Pelicci P.G. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010, 62:18-34.
6. Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012, 11:384-400.
7. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010, 10:23-36.
8. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
9. Stumpel D.J., Schneider P., Seslija L., Osaki H., Williams O., Pieters R., et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 2012, 26:682-692.
10. Bhatla T., Wang J., Morrison D.J., Raetz E.A., Burke M.J., Brown P., et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 2012, 119:5201-5210.
11. Buchwald M., Krämer O.H., Heinzel T. HDACi - targets beyond chromatin. Cancer Lett 2009, 280:160-167.
12. Balasubramanian S., Verner E., Buggy J.J. Isoform-specific histone deacetylase inhibitors: the next step. Cancer Lett 2009, 280:211-221.
13. Weichert W HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009, 280:168-176.
14. Oehme I., Deubzer H.E., Wegener D., Pickert D., Linke J.P., Hero B., et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009, 15:91-99.
15. Milde T., Oehme I., Korshunov A., Kopp-Schneider A., Remke M., Northcott P., et al. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 2010, 16:3240-3252.
16. Moreno D.A., Scrideli C.A., Cortez M.A., de Paula Queiroz R., Valera E.T., da Silva Silveira V., et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 2010, 150:665-673.
17. Sonnemann J., Gruhn B., Wittig S., Becker S., Beck J.F. Increased activity of histone deacetylases in childhood acute lymphoblastic leukaemia and acute myeloid leukaemia: support for histone deacetylase inhibitors as antileukaemic agents. Br J Haematol 2012, 158:664-666.
18. Dordelmann M., Reiter A., Borkhardt A., Ludwig W.D., Gotz N., Viehmann S., et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999, 94:1209-1217.
19. Moricke A., Reiter A., Zimmermann M., Gadner H., Stanulla M., Dordelmann M., et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008, 111:4477-4489.
20. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
21. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008, 409:581-589.
22. Blackwell L., Norris J., Suto C.M., Janzen W.P. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci 2008, 82:1050-1058.
23. Tao Y.F., Pang L., Du X.J., Sun L.C., Hu S.Y., Lu J., et al. Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia. Int J Mol Sci 2013, 14:3376-3394.
24. Advani A.S., Gibson S.E., Douglas E., Jin T., Zhao X., Kalaycio M., et al. Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. BMC Cancer 2010, 10:387.
25. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
26. Qian D.Z., Kachhap S.K., Collis S.J., Verheul H.M., Carducci M.A., Atadja P., et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 2006, 66:8814-8821.
27. Wilson A.J., Byun D.S., Nasser S., Murray L.B., Ayyanar K., Arango D., et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 2008, 19:4062-4075.
28. Stronach E.A., Alfraidi A., Rama N., Datler C., Studd J.B., Agarwal R., et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 2011, 71:4412-4422.
29. Mottet D., Pirotte S., Lamour V., Hagedorn M., Javerzat S., Bikfalvi A., et al. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 2009, 28:243-256.
30. Cadot B., Brunetti M., Coppari S., Fedeli S., de Rinaldis E., Dello R.C., et al. Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells. Cancer Res 2009, 69:6074-6082.
31. Zhang J., Yang Y., Yang T., Liu Y., Li A., Fu S., et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 2010, 103:1215-1220.
32. Einsiedel H.G., Kawan L., Eckert C., Witt O., Fichtner I., Henze G., et al. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Leukemia 2006, 20:1435-1436.
33. Holleman A., Cheok M.H., den Boer M.L., Yang W., Veerman A.J.P., Kazemier K.M., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004, 351:533-542.
34. Lugthart S., Cheok M.H., den Boer M.L., Yang W., Holleman A., Cheng C., et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005, 7:375-386.
35. Wei G., Twomey D., Lamb J., Schlis K., Agarwal J., Stam R.W., et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006, 10:331-342.
36. Spijkers-Hagelstein J.A.P., Schneider P., Hulleman E., de Boer J., Williams O., Pieters R., et al. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia 2012, 26:1255-1265.
37. Fouladi M., Park J.R., Stewart C.F., Gilbertson R.J., Schaiquevich P., Sun J., et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010, 28:3623-3629.
38. Mody R., Li S., Dover D.C., Sallan S., Leisenring W., Oeffinger K.C., et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood 2008, 111:5515-5523.
39. Ontoria J.M., Altamura S., Di Marco A., Ferrigno F., Laufer R., Muraglia E., et al. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. J Med Chem 2009, 52:6782-6789.
40. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
41. Vega R.B., Matsuda K., Oh J., Barbosa A.C., Yang X., Meadows E., et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 1194:555-566.
42. Wellmann S., Guschmann M., Griethe W., Eckert C., Von Stackelberg A., Lottaz C., et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004, 18:926-933.
43. Harvey R.C., Mullighan C.G., Chen I.M., Wharton W., Mikhail F.M., Carroll A.J., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.